The FDA approved Revolution Medicines' Rasonque, the first broad RAS pill for pancreatic cancer. Here is why the stock barely ...
The Chosun Ilbo on MSN
FDA approves RAS-targeting drug that doubles pancreatic cancer survival
An anticancer drug that targets a previously "undruggable" protein in pancreatic cancer, doubling the survival period of ...
RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at ...
The FDA approved daraxonrasib (Rasonque), the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a ...
Revolution Medicines (NasdaqGS:RVMD) received FDA approval for RASONQUE (daraxonrasib) as the first broad RAS-targeted ...
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults ...
Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with ...
The FDA approved Rasonque on Aug 26 for metastatic pancreatic cancer. The pill nearly doubled median survival versus ...
The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 1.
A new FDA-approved drug is giving some pancreatic cancer patients more time. UC researchers helped lay the groundwork for a ...
Daraxonrasib is being hailed as a potential game changer for metastatic pancreatic cancer, roughly doubling survival vs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results